| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
SI-BONE, Inc.$15.95
+0.13 (+0.82%)
F 15Pipeline Score MedTech · Commercial
Market Cap
651.05 M
EPS
-0.39
P/E Ratio
-
Value Trade
7.77 M
SEC Financials
Q1 2026Dilution Risk
Revenue
52.59 M
R&D Expenses
4.19 M
Operating CF
-2.36 M
Total Assets
242.72 M
Total Liabilities
63.78 M
Equity
178.94 M
D/E Ratio
12,345
1.66 %
Week
4.04 %
1 Month
-5.11 %
3 Month
-21.12 %
6 Month
-55.05 %
5 Year
-30.1 %
All Time
Cash Data
Cash Position
144.68 M
Monthly Burn
787.00 K
Runway
182.6 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
386.49 K
52 Week Range
11.48 - 21.89
% held by Insiders
5.38 %
% held by Institutions
104.96 %
Enterprise Value
549.31 M
Total Shares
43.39 M
Short %
14.25 %
Float Shares
41.26 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F15
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 11%
Micro Cap (rank 806 of 905)
Percentile RankSI-BONE, Inc. has significant pipeline risk (15/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SIBN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SIBN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SIBN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SIBN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SIBN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SIBN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SIBNSI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. will participate in the 2026 Truist Securities MedTech Conference in Boston on June 16, 2026. The company will host a fireside chat at 5:40 a.m. PT. Interested investors can register to listen to the conference call, which will also be available for replay on their website for 90 days post-event.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. reported strong financial results for Q1 2026, with worldwide revenue of $52.6 million, an 11.2% increase from the previous year. The company also improved its adjusted EBITDA significantly and raised its revenue guidance for the year. Despite a net loss of $4.3 million, the overall performance indicates a positive trend in growth and market expansion.
Read more →SIBNSI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE, Inc. will participate in the 2026 BofA Securities Healthcare Conference in Las Vegas on May 12, 2026. The company will host a fireside chat to discuss its procedural solutions for compromised bone. Investors can register for the event and access a live audio webcast on the company's website.
Read more →SIBNSI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SI-BONE, Inc. will report its first-quarter 2026 financial results on May 11, 2026, after market close. A conference call will follow at 1:30 p.m. PT, where investors can register to listen. The company has a strong focus on developing solutions for compromised bone and has conducted over 140,000 procedures since its inception.
Read more →SIBNSI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
SI-BONE, Inc. reported strong financial results for Q4 2025, with a 15% increase in worldwide revenue and a positive adjusted EBITDA of $5.1 million. The company achieved a 20% revenue growth for the entire fiscal year and provided optimistic guidance for 2026, expecting revenue between $228.5 million and $232.5 million. Despite improvements, SI-BONE continues to face challenges with operating losses and rising expenses.
Read more →SIBNSI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SI-BONE, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference scheduled for March 2, 2026. The company will host a fireside chat at 7:30 a.m. PT. Investors can register for the call and access a live audio webcast on the company's website, which will be archived for 90 days.
Read more →SIBNSI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026
SI-BONE, Inc. will report its financial results for Q4 and the full year of 2025 on February 23, 2026. The announcement includes details about a conference call for investors, which will take place at 1:30 p.m. PT. The company is recognized for its expertise in procedural solutions related to compromised bone.
Read more →SIBNSI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
SI-BONE, Inc. announced preliminary revenue figures for the fourth quarter and full year 2025, estimating worldwide revenue between $200.8 million and $200.9 million, reflecting a growth of about 20%. The company plans to release detailed financial results in late February 2026. However, these figures are preliminary and may undergo significant adjustments pending audit procedures.
Read more →SIBNSI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
SI-BONE, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 2, 2025. The event will feature a fireside chat with management, providing an opportunity for investors to engage. SI-BONE is recognized for its advancements in treating sacropelvic disorders and has a robust clinical evidence base.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance
SI-BONE, Inc. reported a 21% increase in revenue for Q3 2025, reaching $48.7 million, driven by strong demand for its products. The company also improved its adjusted EBITDA to $2.3 million and raised its 2025 revenue guidance to between $198 million and $200 million. However, operating expenses rose by nearly 12%, impacting profitability.
Read more →SIBNSI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
SI-BONE, Inc. will announce its third quarter 2025 financial results on November 10, 2025. The company, known for its innovative solutions for sacropelvic disorders, will host a conference call at 1:30 p.m. PT. Investors can register for the call and access the webcast on the company's website.
Read more →SIBNSI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025
SI-BONE, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The company will host a fireside chat to discuss its innovations in treating sacropelvic disorders. Investors can listen to the live webcast and access an archived version for 90 days post-event. SI-BONE is recognized for its pioneering work in minimally invasive SI joint surgery.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance Achieved 22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Second Quarter 2025 Financial Highlight
SI-BONE, Inc. reported substantial financial growth in the second quarter of 2025, with a 22% increase in U.S. revenue and a cash flow breakeven status. The company achieved positive Adjusted EBITDA of $1.0 million and an improved net loss of $6.2 million. The firm also announced a leadership transition with the planned retirement of President Tony Recupero, highlighting continued innovation and growing engagement among U.S. physicians. SI-BONE raised its full-year 2025 revenue guidance, anticipating worldwide revenue of $195 million to $198 million.
Read more →SIBNSI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
SI-BONE, Inc. will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The event will feature a fireside chat hosted by the company's management. Interested investors can register for the event and access the live audio webcast on the company's website, which will also be archived for later viewing.
Read more →SIBNSI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025
SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2025 on August 4, 2025, after market close. Management will host a conference call on the same day to discuss the results. The company is recognized for its innovative technologies in surgical treatments for sacropelvic disorders, having supported a significant number of procedures and backed by extensive clinical evidence.
Read more →SIBNSI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
SI-BONE, Inc. will present at the 2025 Truist Securities MedTech Conference in Boston on June 17, 2025. The company's management will host a fireside chat to discuss their innovations in treating sacropelvic disorders. Investors can register to listen to the conference call and access a replay afterward.
Read more →SIBNSI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
SI-BONE, Inc. will participate in the Goldman Sachs 46th Global Healthcare Conference on June 10, 2025. The company will host a fireside chat at 8:20 a.m. PT, which will be accessible to investors via a live webcast. SI-BONE is recognized for its innovative technologies in treating sacropelvic disorders.
Read more →SIBNSI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
SI-BONE, Inc. will present at the BofA Securities Healthcare Conference on May 13, 2025. The company, known for its innovative technologies in treating sacropelvic disorders, will host a fireside chat at 8:40 a.m. PT. Investors can access the live audio of the event via the company's website.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance Achieved 25% worldwide revenue growth and positive adjusted EBITDA First Quarter 2025 Financial Highlights (all comparisons are
SI-BONE, Inc. reported a strong start to 2025, achieving a 25% increase in worldwide revenue and positive adjusted EBITDA of $0.5 million. The company highlighted growth in U.S. revenue, which rose 26.6% to $44.8 million, alongside a gross margin of 79.7%. Despite a net loss of $6.5 million, the firm is optimistic about future profitability and updated its 2025 revenue guidance to between $193.5 million and $197.5 million, reflecting a year-over-year growth of 16% to 18%. The number of active U.S. physicians also grew significantly, which suggests strong onboarding of its innovative products.
Read more →SIBNSI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025
SI-BONE, Inc. has announced it will report its financial results for the first quarter of 2025 on May 5, 2025, following market close. The company is recognized as a leader in developing surgical technologies for sacropelvic disorders and has a significant history of supporting medical professionals in this field. A conference call will be held at 1:30 p.m. PT on the same day for investors to discuss the results. Live audio of the call will be accessible via the company's website.
Read more →SIBNSI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024
SI-BONE, Inc. reported significant financial improvements for the fourth quarter of 2024, achieving a 26% increase in worldwide revenue and reporting positive adjusted EBITDA. The company’s net loss improved notably, showing that operational efficiencies are being realized. Looking ahead, SI-BONE projects a revenue growth of 16% to 17% for 2025, while also indicating improvements in gross margins and further expansion in market reach. The overall operational engagement with healthcare professionals highlights a growing adoption of their products.
Read more →SIBNSI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
SI-BONE, Inc. has announced the date for its fourth-quarter and full-year 2024 financial results, which will be reported on February 24, 2025. The company is recognized for its innovative technologies focused on surgical treatments for sacropelvic disorders and has a strong track record with over 115,000 procedures performed. There will be a conference call for investors to discuss these results, enhancing transparency and engagement.
Read more →SIBNSI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024 Fourth Quarter 2024 worldwide revenue of $48.8 to $49.0 million representing growth of 26% Achieved adjusted EBITDA profitability in the fou
SI-BONE, Inc. announced its preliminary revenue figures for the fourth quarter and full year 2024, highlighting a 26% growth in worldwide revenue, amounting to between $48.8 million and $49.0 million. The company achieved adjusted EBITDA profitability during the same period and noted a significant increase in active physicians in the U.S. by 23%. Despite these positive outcomes, the reported revenues are preliminary and subject to final audit adjustments, with future growth dependent on the successful commercialization of new products and navigating potential reimbursement challenges.
Read more →SIBNSI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SI-BONE, Inc. will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, in New York. The company's management will host a fireside chat at 11:00 a.m. ET, allowing investors to learn more about their technologies for sacropelvic disorders. SI-BONE has established itself as a leader in minimally invasive surgical solutions, having aided numerous surgeries since its inception in 2009. Interested parties can register for the livestream or access the archived session post-event.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif. November, 12 2024 - SI-BONE, Inc. (Nasdaq SIB
SI-BONE, Inc. announced its financial results for the third quarter of 2024, highlighting a 19% revenue growth, totaling $40.3 million. Key improvements included a reduction in net loss to $6.6 million and an expectation to achieve positive Adjusted EBITDA in the upcoming fourth quarter. Operationally, the company reported a growth in active physicians and introduced breakthrough products like the iFuse TORQ TNT. However, challenges remain, such as increased operating expenses and risks related to market conditions and product commercialization.
Read more →SIBNSI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™
SI-BONE has announced that the CMS has approved Transitional Pass-Through payment status for its iFuse Bedrock Granite system, effective January 1, 2025. This decision allows hospitals to receive additional reimbursement for the device used in lumbar spinal fusion procedures without device offset deductions. The TPT payment will remain in effect for three years, ensuring better patient access to innovative surgical solutions for sacropelvic disorders. This move signifies a recognition of the technology's impact on outpatient treatment procedures and the importance of funding for such advanced medical devices.
Read more →SIBNSI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024
SI-BONE, Inc. has announced that it will report its financial results for the third quarter of 2024 on November 12, 2024, following market close. The company will host a conference call at 1:30 PM Pacific Time to discuss these results. SI-BONE is recognized for its innovative solutions in the treatment of sacropelvic disorders and has achieved significant milestones in minimally invasive surgical techniques. Investors can access the conference call through registration and find the webcast on the company's website.
Read more →SIBNSI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation
SI-BONE, Inc. announced the successful completion of first-in-patient procedures using its FDA-designated breakthrough device, the iFuse TORQ TNT Implant System, designed for pelvic fracture fixation. This innovative 3D-printed device aims to enhance surgical efficiency and improve patient outcomes, particularly for individuals with poor bone quality. Leading surgeons have praised the device for its streamlined design and effective performance. The company continues to establish its leadership in addressing unmet needs in the surgical treatment of sacropelvic disorders.
Read more →SIBNSI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024
SI-BONE, Inc. will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. The company's management will host a fireside chat during the event, which will be accessible for investors through audio webcast. SI-BONE has a notable history in developing surgical treatments for sacropelvic disorders, having supported over 3,900 physicians and conducted over 100,000 procedures since 2009. This participation underscores the company's credibility in the healthcare sector.
Read more →SIBNSI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System
SI-BONE, Inc. has received FDA 510(k) clearance and Breakthrough Device Designation for its iFuse TORQ TNT Implant System, which is targeted at treating pelvic fragility fractures. This system is designed specifically for the anatomy of the sacrum and ilium, promising improved fixation and reduced risks associated with traditional therapies. The Breakthrough Device Designation underscores the FDA's recognition of its potential to significantly enhance treatment effectiveness compared to existing methods. This marks SI-BONE's second device to receive such a designation, reaffirming its position in the market for sacropelvic solutions.
Read more →SIBNSI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024
SI-BONE, Inc. will present at the 2024 Canaccord Genuity 44th Annual Growth Conference in Boston on August 14, 2024. The company's management will host a fireside chat to engage with investors. SI-BONE is recognized as a leader in surgical treatment for sacropelvic disorders, with a history of supporting numerous procedures and extensive clinical evidence for its technologies.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Second Quarter 2024 Increases 2024 revenue guidance to $165 million - $167 million Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024
SI-BONE, Inc. reported financial results for Q2 2024, highlighting a 20% increase in worldwide revenue to $40.0 million. The company has revised its 2024 revenue guidance upwards, anticipating earnings between $165 million and $167 million, and expects to reach positive Adjusted EBITDA by the fourth quarter. Despite these positive developments, SI-BONE recorded a net loss of $8.9 million for the quarter. The company also noted an increase in active physicians and a focus on addressing unmet clinical needs, driving growth in procedure volume.
Read more →SIBNSI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024
SI-BONE, Inc. has announced the reporting date for its second quarter 2024 financial results, which will take place after market close on August 5, 2024. Management will hold a conference call to discuss these results, starting at 1:30 p.m. Pacific Time. SI-BONE is recognized for its advanced technologies in surgical treatments for musculoskeletal disorders, having supported numerous surgeons and published substantial clinical evidence regarding its products.
Read more →SIBNSI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024
SI-BONE, Inc. announced its participation in the 2024 Truist Securities MedTech Conference in Boston, set for June 18, 2024. The company will conduct a fireside chat to discuss its pioneering technology in treating musculoskeletal disorders. SI-BONE has a proven history in minimally invasive surgery, having supported over 3,700 surgeons and carried out over 100,000 procedures. The conference provides an opportunity for investors to understand the company's innovations and performance.
Read more →SIBNSI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures
SI-BONE, Inc. announced the launch of the new iFuse Bedrock Granite 9.5 implant for sacroiliac fusion, following FDA clearance and Breakthrough Device Designation. The 9.5 mm diameter implant is designed for patients with smaller anatomical structures and allows for easier placement in surgical procedures. Surgeons have praised the implant for maintaining surgical workflows while enhancing patient outcomes. This development positions SI-BONE to expand its market presence in a billion-dollar sector targeting adult spinal fusion procedures.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the First Quarter 2024 Annual guidance increased to $164 million - $166 million, implying annual growth of 18% - 20%
SI-BONE, Inc. has reported a strong financial performance for Q1 2024, with worldwide revenue reaching $37.9 million, a 16% increase year-over-year. The company has raised its annual revenue guidance to between $164 million and $166 million, reflecting a projected growth of 18% to 20%. Despite the positive revenue growth, SI-BONE experienced an increase in both operating loss and expenses, highlighting ongoing challenges in managing costs. The company is optimistic about future growth, particularly in the pelvic fixation market with the introduction of a new implant.
Read more →SIBNSI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024
SI-BONE, Inc. (Nasdaq: SIBN) announced it will participate in the 2024 BofA Securities Healthcare Conference in Las Vegas on May 14, 2024. Management will host a fireside chat at 2:20 p.m. Eastern Time. Investors can register to listen to the live audio webcast, which will also be archived for 90 days following the event. The company is a leader in surgical treatments for musculoskeletal disorders and has supported extensive surgical procedures, reinforced by significant clinical evidence.
Read more →SIBNSI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024
SI-BONE, Inc. announced it will report its financial results for the first quarter of 2024 on May 6, 2024. The report will be released after market close, followed by a conference call scheduled for 1:30 PM Pacific Time. Investors can access the live audio webcast through the company's website. SI-BONE continues to lead in technologies for minimally invasive surgical treatment of musculoskeletal disorders.
Read more →SIBNSI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024
SI-BONE, Inc. will participate in the Barclays 26th Annual Global Healthcare Conference on March 12, 2024, where management will host a fireside chat. The company, a leader in surgical treatment for musculoskeletal disorders of the sacropelvic anatomy, has performed more than 95,000 procedures. Investors can access the conference call live and will have an opportunity to replay it afterward.
Read more →SIBNSI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance
SI-BONE, Inc. announced its financial results for the fourth quarter and full year of 2023, showcasing significant revenue growth with worldwide revenues rising 31% year-over-year. The company reported a fourth quarter revenue of $38.9 million, led by strong U.S. performance. Despite a reduction in gross margins and an increase in operating expenses, SI-BONE expects continued financial improvements in 2024, projecting revenue growth between 17% and 19% and further operational advancements.
Read more →SIBNSI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
SI-BONE, Inc. has announced it will report its financial results for the fourth quarter and full year of 2023 on February 26, 2024. Following the report, management will host a conference call to discuss the results. As a leader in surgical solutions for musculoskeletal disorders, SI-BONE has a substantial history, supporting numerous surgeons and conducting thousands of procedures backed by clinical evidence. Investors can access the live webcast on the company's website.
Read more →SIBNSI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
SI-BONE, Inc. has received FDA 510(k) clearance for its iFuse Bedrock Granite Implant System in a smaller 9.5 mm diameter, expanding its use to pediatric patients and the S1 trajectory. This new size complements the existing 10.5 mm and 11.5 mm implants and addresses the challenges of screw loosening rates in the spine. The development is supported by clinical evidence and reflects growing interest among surgeons for enhanced pelvic fixation techniques in spinal procedures. The technology aims to improve surgical outcomes by providing a foundational element for multi-segment spinal fusion.
Read more →SIBNSI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023 Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%
SI-BONE, Inc. announced its preliminary revenue for the fourth quarter and full year 2023, highlighting significant growth. The company expects fourth quarter revenue to be between $38.5 and $38.7 million and full year revenue to range from $138.5 to $138.7 million, both indicating growth of over 30%. Additionally, SI-BONE has increased its active surgeon base in the U.S. and maintains a strong cash position. However, the reported figures are preliminary and subject to adjustments pending auditing procedures.
Read more →SIBNSI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
SI-BONE, Inc. will present at the Piper Sandler Healthcare Conference on November 28, 2023. The company's management is scheduled to host a fireside chat at 3:30 p.m. Eastern Time, which investors can listen to by registering online. SI-BONE is recognized for its leadership in surgical treatments for musculoskeletal disorders, having supported over 3,000 surgeons and performed more than 90,000 sacropelvic procedures. The company emphasizes its commitment to innovation in minimally invasive surgical techniques.
Read more →SIBNSI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29%
SI-BONE, Inc. reported record financial results for the third quarter of 2023 with a revenue of $34.0 million, representing approximately 29% growth from the previous year. The company raised its annual revenue guidance to between $136 million and $137 million, indicating continued strong performance. Despite the positive developments, gross margins decreased to 79% primarily due to shifts in product mix and increased operational costs. Furthermore, while the operating loss improved, the company still recorded a net loss of $10.0 million for the quarter.
Read more →SIBNSI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023
SI-BONE, Inc. will present at the Jefferies London Healthcare Conference on November 15, 2023. The company will host a fireside chat aimed at engaging investors. SI-BONE is recognized for its advancements in minimally invasive treatments for musculoskeletal disorders. The live audio of the session will be accessible through their website, with recordings available afterward.
Read more →SIBNSI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023
SI-BONE, Inc. announced it will disclose its financial results for the third quarter of 2023 on November 6, 2023, after market close. A conference call will be held immediately after the announcement for investors and stakeholders. The company, known for its surgical technology concerning musculoskeletal disorders, has a strong clinical backing and aims to provide insights into its financial performance.
Read more →SIBNSI-BONE, Inc. Announces iFuse Bedrock Granite Implant System Compatibility with Certain Medtronic CD Horizon Solera 5.5/6.0 System Rods
SI-BONE, Inc. has announced that certain Medtronic CD Horizon Solera rods meet the compatibility criteria for its iFuse Bedrock Granite implant system. This confirmation enhances the confidence of spine surgeons when using the Granite implant alongside Medtronic's fixation rods. The iFuse Bedrock Granite, recognized as a Breakthrough Device by the FDA, offers significant advantages over existing alternatives and is associated with a substantial reimbursement for procedures by Medicare. SI-BONE has a strong track record in minimally invasive SI joint surgery and continues to innovate in the field.
Read more →SIBNSI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023
SI-BONE, Inc. announced its participation in the Morgan Stanley 21st Annual Global Healthcare Conference scheduled for September 12, 2023. During the event, management will host a fireside chat at 9:30 a.m. ET. The conference presents an opportunity for investors to gain insights into the company’s advancements in musculoskeletal disorders treatment. SI-BONE has established itself as a leader in minimally invasive surgical technologies with extensive clinical backing.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance Annual guidance increased to $132 million - $134 million, implying annual growth of 24%-26%
SI-BONE, Inc. reported strong financial results for the second quarter of 2023, with record revenue of $33.3 million, marking a 30% increase compared to the previous year. The company has raised its annual revenue guidance to between $132 million and $134 million, projecting growth of 24%-26%. Additionally, SI-BONE reported an improvement in operating loss, which decreased by 33% to $12 million. While gross margins have declined, the company's cash reserves remain solid at $169 million, underscoring its overall financial health.
Read more →SIBNSI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023
SI-BONE, Inc. has announced its participation in the Canaccord Genuity 43rd Annual Growth Conference scheduled for August 9, 2023, in Boston. The company will host a fireside chat to discuss its advancements in treating musculoskeletal disorders. SI-BONE has established itself as a leader in minimally invasive surgical treatments, having supported thousands of surgical procedures and maintained a robust clinical evidence foundation. Investors can access the live audio webcast through the company's website, with a replay available for 90 days post-conference.
Read more →SIBNSI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023
SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2023 on August 7, 2023, after market close. A conference call will follow the announcement, allowing investors to engage with management. The company's leadership in the surgical treatment of musculoskeletal disorders has been established through extensive clinical evidence and successful procedures. This release sets the stage for stakeholders to assess the company's performance.
Read more →SIBNSI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023
SI-BONE, Inc. has announced its participation in the 2023 Jefferies Healthcare Conference scheduled for June 7, 2023, in New York. During the event, the company will host a fireside chat where management will likely discuss its advancements in musculoskeletal disorder treatments. SI-BONE is recognized as a leader in minimally invasive SI joint surgery, having assisted over 3,000 surgeons and conducted extensive clinical research. Investors can access the conference through registration and will have the opportunity to replay the event afterward.
Read more →SIBNSI-BONE Announces Pricing of Public Offering of Common Stock
SI-BONE, Inc. has announced the pricing of its public offering of 3,775,000 shares of common stock at $22.00 per share, with expected gross proceeds of about $77 million. The offering includes shares from both the company and a selling stockholder. The transaction is set to close on May 9, 2023, pending customary closing conditions. Major financial institutions are involved as joint book-running managers, and the offering follows the filing of a shelf registration statement with the SEC.
Read more →SIBNSI-BONE Announces Launch of Public Offering of Common Stock
SI-BONE, Inc. has announced a public offering of 3,775,000 shares of its common stock to raise capital for its operations. Reputable underwriters including BofA Securities and Morgan Stanley are involved in the offering, which is subject to market conditions and does not guarantee success. The press release also highlights the possible impacts of market fluctuations on the offering's completion and terms. Additionally, it provides details on obtaining the related prospectus from the SEC and the underwriters.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the First Quarter 2023 and Increases Annual Guidance Annual guidance increased to $128 million - $131 million, implying annual growth of 20%-23%
SI-BONE, Inc. reported a strong financial performance for the first quarter of 2023, with record revenues of $32.7 million, reflecting a 46% increase compared to the prior year. The company has improved its annual guidance to between $128 million and $131 million, indicating expected growth of 20%-23%. Despite higher operating expenses and a slight decline in gross margin, the active surgeon base has expanded significantly, supporting increased demand for SI-BONE's product offerings. The CEO expressed confidence in the company’s growth trajectory as it continues to innovate within the musculoskeletal sector.
Read more →SIBNSI-BONE to Present at Bank of America Merrill Lynch 2023 Global Healthcare Conference
SI-BONE, Inc. will participate in the 2023 Bank of America Merrill Lynch Global Healthcare Conference on May 9, 2023, in Las Vegas. The company will host a fireside chat, providing an opportunity to engage with investors. SI-BONE is recognized for its iFuse Implant System, which has been instrumental in treating musculoskeletal disorders and is supported by comprehensive clinical evidence.
Read more →SIBNSI-BONE To Report First Quarter 2023 Financial Results on May 1, 2023
SI-BONE, Inc. has announced that it will report its first quarter 2023 financial results on May 1, 2023, after the market closes. The company will hold a conference call to discuss these results, starting at 1:30 p.m. PT/4:30 p.m. ET. SI-BONE is recognized for its innovative solutions in treating sacropelvic disorders, notably with its iFuse Implant System, which has maintained strong adoption among surgeons. The upcoming financial report is anticipated by investors as an important indicator of the company's performance.
Read more →SIBNSI-BONE, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Issues 2023 Guidance
SI-BONE, Inc. reported its financial results for Q4 and full year 2022, noting a 27% increase in worldwide revenue to $32.0 million for Q4. The company also provided guidance for 2023, expecting revenue growth of approximately 17% to 19%. Despite the positive financial results and operational growth, SI-BONE reported a net loss of $11.2 million, illustrating ongoing financial challenges. The results indicate both opportunities for growth and risks associated with high operating costs and currency fluctuations affecting international revenue.
Read more →SIBNSI-BONE To Report Fourth Quarter 2022 Financial Results on February 27, 2023
SI-BONE, Inc. announced it will report its fourth quarter 2022 financial results on February 27, 2023, after market close. A conference call with management will follow the report, providing investors an opportunity to engage with the company. SI-BONE has established itself as a leader in surgical treatments for musculoskeletal disorders, showing a significant operational history and support from insurance providers for its flagship product, the iFuse Implant System.
Read more →SIBNSI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2022 Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26% Fiscal Year 2022 revenue of $106.1 - $106.3 million
SI-BONE, Inc. reported preliminary and unaudited revenue figures for the fourth quarter and full year 2022, indicating significant growth. The fourth quarter revenue is anticipated to be between $31.7 million and $31.9 million, marking a roughly 26% increase from the previous year. For the entire fiscal year, revenue is expected to reach between $106.1 million and $106.3 million, which reflects an approximately 18% growth. The company enjoyed a notable increase in the number of active surgeons utilizing its technology, highlighting its strong market presence and demand for its iFuse Implant System.
Read more →SIBNSI-BONE to Host a Virtual Fireside Chat at the 25th Annual Needham Growth Conference
SI-BONE, Inc. will participate in the 25th Annual Needham Growth Conference, hosting a virtual fireside chat on January 12, 2023. The event will be accessible through a live webcast and will be archived for 90 days. SI-BONE is known for its iFuse Implant System, which has solidified its leadership in minimally invasive surgical treatment for SI joint fusion.
Read more →SIBNSI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite Implant System
SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced an additional FDA clearance for iFuse Bedrock Granite®. N
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance SANTA CLARA, Calif. November 7, 2022 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financia
Read more →SIBNSI-BONE To Report Third Quarter 2022 Financial Results on November 7, 2022
SANTA CLARA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2022 after market clo
Read more →SIBNSI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference
SANTA CLARA, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annu
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Second Quarter 2022
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022 SANTA CLARA, Calif. August 8, 2022 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quar
Read more →SIBNSI-BONE To Present at The Canaccord Genuity 42nd Annual Growth Conference 2022
SANTA CLARA, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Laura Francis, CEO, and Anshul Maheshwari, CFO will be presenting at the u
Read more →SIBNSI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022
SANTA CLARA, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2022 after market cl
Read more →SIBNSI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ Implant System
SANTA CLARA, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced an FDA clearance for iFuse-TORQ® for pelvic fractu
Read more →SIBNSI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion Technology
SANTA CLARA, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite Impl
Read more →SIBNSI-BONE, Inc. Reports First Quarter 2022 Financial Results
SI-BONE, Inc. Reports First Quarter 2022 Financial Results SANTA CLARA, Calif. May 9, 2022 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended Ma
Read more →SIBNSI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment
SANTA CLARA, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the Centers for Medicare and Medicaid Services (CMS)
Read more →SIBNSI-BONE To Present at BofA Securities 2022 Healthcare Conference
SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2022 Bank of America He
Read more →SIBNSI-BONE To Report First Quarter 2022 Financial Results on May 9, 2022
SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2022 after market cl
Read more →SIBNSI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance SANTA CLARA, Calif. February 28, 2022 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, to
Read more →SIBNSI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
SANTA CLARA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year 2021 afte
Read more →SIBNSI-BONE Announces Revenue for the Fourth Quarter and Full Year 2021 Preliminary 2021 revenue of $89.8-90.1 million represents growth of 22%-23%
SI-BONE Announces Revenue for the Fourth Quarter and Full Year 2021 Preliminary 2021 revenue of $89.8-90.1 million represents growth of 22%-23% SANTA CLARA, Calif., January 10, 2022 - SI-BONE, Inc. (Nasdaq SIBN) ("SI-BONE" or the "Company"), a medical device company dedicated t
Read more →SIBNSI-BONE to participate in 24th Annual Needham Virtual Growth Conference
SANTA CLARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced management is scheduled to participate in the following i
Read more →SIBNSI-BONE, Inc. Announces Updated Exclusive Blue Cross Blue Shield Association Evidence Street Opinion, and New Coverage Policies from Arkansas Blue Cross Blue Shield and Walmart Plans from BlueAdvantage Administrators of Arkansas
SANTA CLARA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced that Blue Cross Blue Shield Association (BCBSA) Evidence
Read more →SIBNSI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial Guidance
SI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial Guidance SANTA CLARA, Calif. November 8, 2021 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported f
Read more →SIBNSI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021
SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market clo
Read more →SIBNSI-BONE, Inc. Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally Invasive SI Joint Fusion
SANTA CLARA, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced that UnitedHealthcare has changed its minimally invasive
Read more →SIBNSI-BONE to Participate in Upcoming Conferences
SANTA CLARA, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that it will be participating in the following upcoming investor conferences:
Read more →SIBNSI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem Record Second Quarter 2021 Worldwide Revenue of $22.2 million
SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem Record Second Quarter 2021 Worldwide Revenue of $22.2 million SANTA CLARA, Calif. August 2, 2021 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving
Read more →SIBNSI-BONE, Inc. Announces Anthem, Inc. Adopts Coverage Guidelines for Sacroiliac Joint Fusion Exclusive to the Triangular iFuse Implant System for Its More Than 40 Million Members
SANTA CLARA, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Anthem, Inc. will cover minimally invasive SI joint f
Read more →SIBNSI-BONE to Present at the Canaccord Genuity 41st Annual Growth Conference
SANTA CLARA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Canaccord Genuity 41st A
Read more →SIBNSI-BONE To Report Second Quarter 2021 Financial Results on August 2, 2021
SANTA CLARA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2021 after market cl
Read more →SIBNSI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse Implant System
SANTA CLARA, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Centene Corporation has established a positive cover
Read more →SIBNSI-BONE, Inc. Announces Publication of iFuse-3D Implant Clinical Study Results Showing Accelerated Fusion, Immediate and Sustained Clinical Improvements and Reduction in Opioid Use
SANTA CLARA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy announced the publication of 2-year results from SALLY (Study of bone grow
Read more →SIBNSI-BONE, Inc. Announces the Introduction of the SI-BONE SImulator™ Powered by Medability for iFuse Surgeon Training and Education
SANTA CLARA, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the worldwide launch of the SI-BONE SImulator™. The SI-B
Read more →SIBNSI-BONE to Present at the 2021 JMP Securities Life Sciences Conference
SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2021 JMP Securities Life
Read more →SIBNSI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance
SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance SANTA CLARA, Calif. May 3, 2021 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fin
Read more →SIBNSI-BONE to Present at the 7th Annual Truist 2021 Life Sciences Summit and the 2021 Bank of America Health Care Conference
SANTA CLARA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 7th Annual Truist
Read more →SIBNSI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors
SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company’s Ch
Read more →SIBNSI-BONE To Report First Quarter 2021 Financial Results on May 3, 2021
SANTA CLARA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2021 after market cl
Read more →SIBNSI-BONE, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Issues 2021 Financial Guidance
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Issues 2021 Financial Guidance SANTA CLARA, Calif. March 8, 2021 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, toda
Read more →SIBNSI-BONE To Report Fourth Quarter and Full Year 2020 Financial Results on March 8, 2021
SANTA CLARA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year 2020 afte
Read more →SIBNSI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue Laura Francis to Become Chief Executive Officer Jeff Dunn to Become Executive Chairman and Tony Recupero to Become President.
SI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue Laura Francis to Become Chief Executive Officer Jeff Dunn to Become Executive Chairman and Tony Recupero to Become President. SANTA CLARA, Calif., January 7, 2021 - SI-BONE, Inc. (Nasdaq SIBN) ("SI-BONE"
Read more →SIBNSI-BONE, Inc. Announces that Updated ISASS Policy and Guidelines on MIS SI Joint Fusion Support Only Lateral Transiliac MIS Procedures
SANTA CLARA, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the International Society for the Advancement of Spi
Read more →SIBNSI-BONE, Inc. Announces that Priority Health Became the 36th Payor with Exclusive iFuse Coverage Policy
SANTA CLARA, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that effective November 25, 2020, Priority Health Michiga
Read more →SIBNSI-BONE to Present at the 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference
SANTA CLARA, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 23rd Annual Needha
Read more →SIBNSI-BONE, Inc. Announces that Humana Establishes Exclusive Coverage for iFuse in MIS SI Joint Fusion Procedures
SANTA CLARA, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced that Humana has revised its coverage policies to cover mi
Read more →SIBNSI-BONE, Inc. Reports Third Quarter 2020 Financial Results and 2020 Revenue Guidance
SI-BONE, Inc. Reports Third Quarter 2020 Financial Results and 2020 Revenue Guidance SANTA CLARA, Calif. November 2, 2020 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial r
Read more →SIBNSI-BONE To Report Third Quarter 2020 Financial Results on November 2, 2020
SANTA CLARA, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2020 after market clo
Read more →SIBNSI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance
SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance SANTA CLARA, Calif. October 8, 2020 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic an
Read more →SIBNSI-BONE, Inc. to Host Virtual KOL Surgeon Panel at NASS
SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Jeffrey Dunn, Chairman and CEO, will host a virtual
Read more →SIBNSI-BONE to Present at the 2020 Cantor Global Healthcare Conference
SANTA CLARA, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the company will be participating in the upcoming 2020 Cantor Global Heal
Read more →SIBNSI-BONE to Present at the Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference
SANTA CLARA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18
Read more →SIBNSI-BONE, Inc. Announces Exclusive, Positive iFuse Coverage decision by Medica
SANTA CLARA, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Medica published an exclusive, positive iFuse covera
Read more →SIBNSI-BONE, Inc. Reports Second Quarter 2020 Financial Results
SI-BONE, Inc. Reports Second Quarter 2020 Financial Results SANTA CLARA, Calif. August 3, 2020 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ende
Read more →SIBNSI-BONE to Present at the 40th Annual Canaccord Genuity Growth Conference
SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 40th Annual Canacc
Read more →SIBNSI-BONE To Report Second Quarter 2020 Financial Results on August 3, 2020
SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2020 after market cl
Read more →SIBNSI-BONE, Inc. Announces $40 Million Debt Re-Financing
SANTA CLARA, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that it has re-financed its existing credit facility. Pro
Read more →SIBNSI-BONE, Inc. Announces Aetna Establishes Positive Coverage for MIS SI Joint Fusion using the Triangular iFuse Implant System
New positive coverage policy further validates acceptance of iFuse as an important treatment option for patients with chronic sacroiliac joint dysfunction SANTA CLARA, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device c
Read more →SIBNSI-BONE to Present at the Bank of America Securities 2020 Health Care Conference
SANTA CLARA, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the company will be participating in the upcoming Bank of America Securitie
Read more →SIBNSI-BONE, Inc. Reports First Quarter 2020 Financial Results
SI-BONE, Inc. Reports First Quarter 2020 Financial Results SANTA CLARA, Calif. May 4, 2020 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended Ma
Read more →SIBNSI-BONE To Report First Quarter 2020 Financial Results on May 4, 2020
SANTA CLARA, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2020 after market cl
Read more →SIBNSI-BONE, Inc. Provides Business Update in Response to COVID-19 Pandemic
SI-BONE, Inc. Provides Business Update in Response to COVID-19 Pandemic SANTA CLARA, Calif. April 2, 2020 - SI-BONE, Inc. (Nasdaq SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today provided an update on the actions it
Read more →SIBNSI-BONE, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results Reiterates Full Year 2020 Financial Outlook
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results Reiterates Full Year 2020 Financial Outlook SANTA CLARA, Calif. March 9, 2020 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anat
Read more →SIBNSI-BONE To Report Fourth Quarter 2019 Financial Results on March 9, 2020
SANTA CLARA, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2019 after market c
Read more →SIBNSI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2019 and Provides Full Year 2020 Revenue Guidance
SANTA CLARA, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the fourth quarter and full year 2019. Preli
Read more →SIBNSI-BONE, Inc. Announces CIGNA Establishes Positive Coverage for MIS SI Joint Fusion using the iFuse Implant System
SANTA CLARA, Calif., Dec. 13, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that CIGNA has established a positive coverage policy for
Read more →SIBNSI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors
SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its Board of Directors, eff
Read more →SIBNSI-BONE to Participate at the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019
SANTA CLARA, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management will participate in the upcoming 31st Annual Piper Jaffray Heal
Read more →SIBNSI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue Guidance
SI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue Guidance SANTA CLARA, Calif. November 11, 2019 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today r
Read more →SIBNSI-BONE Announces Medicare Physician Payment Increase of 27% for Minimally Invasive SI Joint Fusion
SANTA CLARA, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the Centers for Medicare and Medicaid Services (CMS) has u
Read more →SIBNSI-BONE To Report Third Quarter 2019 Financial Results on November 11, 2019
SANTA CLARA, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2019 after market clo
Read more →SIBNSI-BONE, Inc. Announces Publication of Five-Year Prospective Study Results on 103 Patients Treated with Triangular Titanium iFuse Implant System
SANTA CLARA, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced the publication of 5-year results from a long-term pros
Read more →SIBNSI-BONE, Inc. Announces Wellmark Blue Cross Blue Shield Establishes Positive Coverage for MIS SI Joint Fusion Using iFuse
SANTA CLARA, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced that Wellmark Blue Cross Blue Shield (BCBS) has establi
Read more →SIBNSI-BONE to Present at the 17th Annual Morgan Stanley Global Healthcare Conference on September 10, 2019
SANTA CLARA, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management will participate in the upcoming 17th Annual Morgan Stanley Glo
Read more →SIBNSI-BONE, Inc. Reports Second Quarter 2019 Financial Results
SI-BONE, Inc. Reports Second Quarter 2019 Financial Results SANTA CLARA, Calif. August 6, 2019 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ende
Read more →SIBNSI-BONE to Present at the Canaccord Growth Conference on August 8, 2019
SANTA CLARA, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management will participate in the upcoming 2019 Canaccord Growth Conferen
Read more →SIBNSI-BONE To Report Second Quarter 2019 Financial Results on August 6, 2019
SANTA CLARA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2019 after market cl
Read more →SIBNSI-BONE’s iFuse Implant System Surpasses 40,000 Procedures
SANTA CLARA, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the iFuse Implant System® has been used in more than
Read more →SIBNSI-BONE Announces the Addition of Mark Foley and Heyward Donigan to the Board of Directors
SANTA CLARA, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced that Mark J. Foley and Heyward R. Doniga
Read more →SIBNSI-BONE to Present at the 2019 JMP Securities Life Sciences Conference
SANTA CLARA, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management will participate in the upcoming 2019 JMP Securities Life Scien
Read more →SIBNSI-BONE, Inc. Reports First Quarter 2019 Financial Results
SI-BONE, Inc. Reports First Quarter 2019 Financial Results SANTA CLARA, Calif. May 8, 2019 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended Ma
Read more →SIBNSI-BONE to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
SANTA CLARA, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management will participate in the upcoming 2019 Bank of America Merrill
Read more →SIBNSI-BONE To Report First Quarter 2019 Financial Results on May 8, 2019
SANTA CLARA, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2019 after market cl
Read more →SIBNSI-BONE, Inc. Announces FDA Clearance of iFuse Bedrock™ Novel Spinopelvic Fixation Technology
SANTA CLARA, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley based medical device company dedicated to solving musculoskeletal disorders of the spinopelvic anatomy, today announced that it received an additional 510(k) clearance from the
Read more →SIBNSI-BONE, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results Provides Full Year 2019 Financial Outlook
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ ____________________________________________________________________________ Pursuant to Section 13 or 15(d) of the Securities Exchange Act
Read more →SIBNSI-BONE, Inc. Announces Journal of Bone and Joint Surgery (JBJS) Publishes 2-Year Results from iMIA, a European Multicenter Randomized Controlled Trial (RCT) of SI Joint Fusion with iFuse Implant System vs Conservative Care
SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that pioneered minimally invasive surgery of the sacroiliac (SI) joint with the iFuse Implant System® (iFuse), announced publication of 2-year results from iMIA (iFuse I
Read more →SIBNSI-BONE to Present at the Canaccord Genuity Musculoskeletal Conference
SANTA CLARA, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the company will be participating in
Read more →SIBNSI-BONE To Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
SANTA CLARA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced it will report financial results for
Read more →SIBNSI-BONE, Inc. Announces Additional Exclusive Coverage Policies for iFuse
SANTA CLARA, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that pioneered minimally invasive surgery of the sacroiliac (SI) joint with the iFuse Implant System® (iFuse) announced the addition of several exclusive coverage policie
Read more →SIBNSI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2018
SANTA CLARA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System, today announced preliminary unaudited revenue for the four
Read more →SIBNSI-BONE to Present at the 37th Annual J.P. Morgan Healthcare Conference
SANTA CLARA, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the company will be participating in
Read more →SIBNSI-BONE, Inc. Announces Blue Cross Blue Shield of Arizona (BCBS AZ) Establishes Positive Coverage for MIS SI Joint Fusion Exclusively with the Triangular Titanium iFuse Implant System
SANTA CLARA, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- SI-BONE, Inc., a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced that Blue Cross Blue Shield of Arizona (BCBS AZ), based
Read more →SIBNSI-BONE, Inc. Reports Third Quarter 2018 Financial Results
SI-BONE, Inc. Reports Third Quarter 2018 Financial Results SANTA CLARA, Calif. November 29, 2018 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System, today reported
Read more →Competitive Position
How SIBN ranks across every disease it competes inCompetitive Position is a premium feature
See how SIBN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial